The human genome project has allowed for the rapid identification of a large number of protein families based on similarities in their genetic sequences. In the present study, I report the functional characterization of a 44 kDa protein that functions in cardiolipin synthesis and remodeling. Although it is present in most tissues, it is abundant in multiple brain regions including olfactory bulbs, hippocampus, cerebellum, cortex, and brain stem, and is detectable in both primary neurons and glial cells. In assays performed in vitro, this protein significantly increased the incorporation of [14C]oleoyl-CoA into phosphatidylinositol and CL using either lysophosphatidylinositol, or monolysocardiolipin or dilysocardiolipin as acyl acceptors, respectively. This protein did not display significant acyltransferase activity with a number of other lysophospholipid acyl acceptors. Overexpressing this enzyme in HEK-293 cells increased total CL content, but did not significantly affect levels of other glycerophospholipids. Analysis of the fatty acyl profile of CL from cells overexpressing this protein indicated increased total saturated fatty acids, particularly stearate, palmitate, and myristate, and increased levels of n-3 polyunsaturated fatty acids α-linoleic acid (18:3n-3), eicosatrienoic acid (20:3n-3), and eicosapentanoic acid (20:5n-3). In accordance with its observed role in CL remodeling, subcellular localization of this protein was predominately mitochondrial. This protein is also regulated during embryogenesis, and in varying metabolic states.

No description available.

No description available.

No description available.

No description available.

No description available.

No description available.

No description available.

No description available.

The province of Manitoba has set a goal of reducing time from suspicion of cancer to treatment to a target of sixty days. To attain this goal, a baseline understanding of current time intervals is required. This study examined system, diagnostic and treatment delay in adult patients (> 17) diagnosed with Lymphomas from 2005 to 2010 using administrative data (Manitoba Cancer Registry, Manitoba Health billing data and Hospital Abstract data) and a chart review of a random subset of patients. A triangulated data approach was used to identify suspicion of lymphoma and milestones in the patient journey and to measure delays in diagnosis and treatment. Using an iterative consultative process, an algorithm was built to identify index events likely related to subsequent lymphoma diagnosis. Then, claims data was searched for a referring provider for each index event. The last visit with a referring provider, prior to the first index event, was selected as date of high suspicion. The study found that 14.8% of patients met the provincial target of less than sixty days from suspicion to treatment. Median time from high suspicion to treatment, referred to as system delay, was 128 days and the median time from diagnosis to treatment was 41 days. Time to diagnosis accounted for two thirds of system delay. In conclusion, this study demonstrated the merit of a triangulated approach. As well the clinical pathway developed and the target timelines for milestones have operational value and can be used to direct process improvements to shorten delays for future patients. / February 2017